Observational studyAsian Pacific journal of cancer prevention : APJCP2026
Prevalence of Cancer Cachexia Among Breast Cancer Patients in Pakistan, Assessed Using the Mini-CASCO Scoring System.
Observational study in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to estimate the prevalence, severity, and multidomain impact of cancer cachexia among Pakistani breast cancer patients, using the validated Mini-CASCO scoring system.
methodsWe conducted an observational, cross-sectional study from February to December 2024 at Fauji Foundation Hospital (FFH), Rawalpindi. Eligible participants were female patients aged 18 years or older, with stage I-III breast cancer, receiving chemotherapy. Cachexia was assessed using the Mini-CASCO, which encompasses body composition, inflammation, anorexia, physical performance, and quality of life. Demographic, anthropometric, biochemical, and validated patient-reported outcomes were collected. Group differences between cachectic and non-cachectic patients were analyzed using the chi-square (χ²) test, with statistical significance set at p < 0.05.
resultsOf 134 participants (mean age: 45.2 ± 8.3 years), the prevalence of cachexia was 61.9% (95% CI: 53.4-70.0). The mean Mini-CASCO score was 45.7 ± 9.3 (95% CI: 43.7-47.8), indicating moderate cachexia. The severity distribution was 16.9% mild, 49.4% moderate, and 33.7% severe; no terminal cases were detected. Body weight and composition (12.7 ± 4.3) and anorexia (9.2 ± 2.6) were the most impaired domains. Compared with non-cachectic patients, those with cachexia had significantly greater inflammation (11.2 vs. 7.4, p < 0.001), anorexia (10.9 vs. 6.8, p < 0.001), and poorer quality of life (6.2 vs. 4.7, p < 0.001).
conclusionMore than six in ten patients exhibited cachexia a rate substantially higher than global estimates highlighting its neglected burden in low- and middle-income country (LMIC) oncology settings. Early, structured assessment using the Mini-CASCO, along with the integration of multimodal nutritional and supportive interventions, is urgently needed to reduce preventable morbidity and mortality. Future multicenter, longitudinal studies are essential to guide evidence-based cachexia management in LMICs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.